We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+18.45%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$203M
Cap. Flow
+$116M
Cap. Flow %
10.49%
Top 10 Hldgs %
77.46%
Holding
28
New
8
Increased
10
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$83.1M
2
MDXG icon
MiMedx Group
MDXG
+$73.1M
3
NUVA
NuVasive, Inc.
NUVA
+$38.3M
4
CORT icon
Corcept Therapeutics
CORT
+$34.4M
5
URGN icon
UroGen Pharma
URGN
+$32.6M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$79M
2
MYGN icon
Myriad Genetics
MYGN
+$71.4M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$60.2M
4
KERX
Keryx Biopharmaceuticals Inc
KERX
+$37.1M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$24M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPPI
1
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$140M 12.64%
7,383,466
-1,325,665
-15% -$24M
CORT icon
2
Corcept Therapeutics
CORT
$12.8B
$104M 9.43%
5,779,506
+1,897,283
+49% +$34.4M
AMRN
3
Amarin Corp
AMRN
$298M
$98.2M 8.87%
1,223,826
-8,638
-0.7% -$595K
GWPH
4
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$89.2M 8.05%
675,492
+73,445
+12% +$8.63M
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$84.2M 7.6%
+2,649,285
New +$83.1M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$76.8M 6.94%
3,644,438
+138,834
+4% +$3.17M
MDXG icon
7
MiMedx Group
MDXG
$622M
$75.5M 6.82%
+5,990,682
New +$73.1M
PCRX icon
8
Pacira BioSciences
PCRX
$1.06B
$73.1M 6.61%
1,602,334
+222,200
+16% +$8.81M
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
$66.9M 6.04%
2,079,311
+76,792
+4% +$2.51M
ARGX icon
10
argenx
ARGX
$54.6B
$49.5M 4.47%
+783,869
New +$25.7M
SVRA icon
11
Savara
SVRA
$1.14B
$40.9M 3.69%
+2,756,012
New +$31.6M
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
$39.5M 3.57%
+675,000
New +$38.3M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$36.7M 3.31%
2,349,792
+2,248,372
+2,217% +$30.1M
URGN icon
14
UroGen Pharma
URGN
$2B
$34.1M 3.08%
+916,450
New +$32.6M
PACB icon
15
Pacific Biosciences
PACB
$460M
$18.7M 1.68%
7,065,920
+164,492
+2% +$576K
VCEL icon
16
Vericel Corp
VCEL
$2.43B
$18.4M 1.66%
3,381,303
+356,969
+12% +$1.65M
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
$17.5M 1.58%
4,473,607
+4,104,309
+1,111% +$13.6M
OXFD
18
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$15.6M 1.41%
+1,119,887
New +$16.4M
ADMA icon
19
ADMA Biologics
ADMA
$2.01B
$10.8M 0.98%
3,367,635
+2,093,702
+164% +$5.86M
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.83B
$9.21M 0.83%
142,978
-25
-0% -$1.55K
CVRS
21
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$6.05M 0.55%
5,986,005
-5,877,348
-50% -$6.65M
IOVA icon
22
Iovance Biotherapeutics
IOVA
$2.09B
$1.86M 0.17%
+232,396
New +$1.87M
SPNE
23
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$217K 0.02%
21,428
-22,199
-51% -$228K
GMED icon
24
Globus Medical
GMED
$10.9B
– –
-554,699
Closed -$16.5M
MYGN icon
25
Myriad Genetics
MYGN
$507M
– –
-1,973,177
Closed -$71.4M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Consonance Capital Management held 28 positions worth $1.11B, up 22% from $904M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Consonance Capital Management deployed $116M of net new capital in Q4 2017, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Radius Health, Inc.: 2,649,285 shares worth $84.2M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Spectrum Pharmaceuticals Inc, an estimated $24M trimmed.

  • Consonance Capital Management's largest Q4 2017 buy was Radius Health, Inc.: 2,649,285 shares worth $84.2M.
  • Consonance Capital Management added most to Corcept Therapeutics in Q4 2017, an estimated $34.4M increase.
  • Consonance Capital Management's biggest Q4 2017 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $24M.
  • Consonance Capital Management fully exited PTC Therapeutics in Q4 2017, selling an estimated $79M.
  • Consonance Capital Management's ten largest holdings make up 77% of its $1.11B portfolio in Q4 2017.
  • Consonance Capital Management opened 8 new positions and closed 5 in Q4 2017.
  • Consonance Capital Management's portfolio value rose 22% quarter-over-quarter to $1.11B.

Based on Consonance Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.